Condition
Veisalgia
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 1 (1)
P 2 (2)
Trial Status
Unknown1
Completed1
Not Yet Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT06722898Phase 2Not Yet Recruiting
Rapid BAC Reduction with Nutraceutical Blend Study
NCT02737397Phase 2CompletedPrimary
Safety and Efficacy of a Combination Product for the Prevention of Veisalgia
NCT03183297Phase 1UnknownPrimary
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001
Showing all 3 trials